Reducing Barriers To Clinical Trial Participation In A New Age Of Cancer Research: A Call To Action At ASCO

By Joe O’Connell, MD, Vice President and Global Therapeutic Lead for Hematology/ Oncology, INC Research/inVentiv Health Clinical Division

As new forms of cancer therapies proliferate – from vaccines, to immunotherapeutic stimulatory and inhibitory molecules, to antibody drug conjugates – answering questions concerning dose, combination and sequence across many cancers and molecular subsets is undeniably critical but, given the low rate of participation in oncology clinical trials, may ultimately become impossible in many cases.